UNION therapeutics A/S - Crunchbase Company Profile & Funding

Overview

UNION therapeutics A/S

Heat Score

Company Performance Metrics

Score

Trend

About These Metrics

AI Content may contain mistakes and is not legal, financial or investment advice.

Learn more.

Growth Score - The measure of growth based on company activity, operational metrics, and investments

Growth Trend - The change in the growth score over the given time period

Heat Score - The measure of the market interest, media activity, and Crunchbase profile activity

Heat Trend - The change in the heat score over the given time period

Recent Milestones

Raised Funding Round

Jan 1, 1970

Lorem ipsum dolor sit amet, consectetur

Raised Funding Round

Jan 1, 1970

Lorem ipsum dolor sit amet, consectetur

Raised Funding Round

Jan 1, 1970

Lorem ipsum dolor sit amet, consectetur

See more interactive data and historical milestones on desktop for the best experience

About UNION therapeutics A/S

CB Rank

406461

UNION therapeutics A/S is a privately held, clinical stage, pharmaceutical company.

Founded

obfuscation

Private

Hellerup, Hovedstaden, Denmark

11-50

uniontherapeutics.com/

Biotechnology

Health Care

Life Science

Pharmaceutical

Key People

Kim Domela Kjøller: Chief Executive Officer
Morten O. A. Sommer: Co Founder and CSO
Past Role: Microlytic, Founder

Details

Legal Name

UNION therapeutics A/S

Operating Status

Active

Company Type

For Profit

Founders

Morten O. A. Sommer, Rasmus Vendler Toft-Kehler

About the Company

UNION therapeutics A/S is a privately held, clinical stage, pharmaceutical company dedicated to the development of molecules exhibiting both immunomodulatory and microbiological effects. UNION is focused on the treatment of inflammatory skin disease and COVID-19, but the chemistry platform is applicable across a wide range of diseases.

Phone Number

+45 5366 3044

Contact Email

info@uniontherapeutics.com

Predictions & Insights

Growth Prediction

See this Growth Prediction

Top Contributing Factors

Growth Insight

Products & Services

Orismilast

An oral PDE4 inhibitor drug candidate targeting inflammatory and immunological diseases such as atopic dermatitis, hidradenitis suppurativa, psoriasis, and ulcerative colitis.

UNI836

A drug candidate developed for the treatment of canine pyoderma, a common bacterial skin infection in dogs, licensed to Ceva Santé Animale for veterinary development and commercialization.

Research & Development

UNION therapeutics A/S is

obfuscated obfuscated obfuscated obfuscated obfuscated obfuscated obfuscated obfuscated obfuscated obfuscated obfuscated obfuscated obfuscated obfuscated obfuscated obfuscated obfuscated

...